AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

60.35USD
30 Jan 2015
Change (% chg)

$-2.77 (-4.39%)
Prev Close
$63.12
Open
$62.00
Day's High
$62.64
Day's Low
$60.12
Volume
3,448,354
Avg. Vol
1,753,708
52-wk High
$70.76
52-wk Low
$45.51

ABBV.N

Chart for ABBV.N

About

AbbVie Inc. (AbbVie) is a global research-based pharmaceuticals company. The Company’s products are used to treat chronic autoimmune diseases, including rheumatoid arthritis, psoriasis, and Crohn’s disease; human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease, and complications associated with... (more)

Overall

Beta: --
Market Cap(Mil.): $96,164.82
Shares Outstanding(Mil.): 1,593.45
Dividend: 0.49
Yield (%): 3.25

Financials

  ABBV.N Industry Sector
P/E (TTM): 26.16 37.76 38.54
EPS (TTM): 2.31 -- --
ROI: 17.19 18.79 18.06
ROE: 90.29 19.44 18.83
Search Stocks

UPDATE 2-AbbVie expects hep C drug sales to top $3 billion per year

Jan 30 - AbbVie Inc's chief executive said on Friday the company's new oral hepatitis C treatment Viekira Pak has the potential to capture a "meaningful share" of the U.S. market, where it is competing against Gilead Sciences .

30 Jan 2015

AbbVie says it will take meaningful share of hepatitis C market

Jan 30 - AbbVie Inc's top executive said on Friday that the company's new hepatitis C treatment Viekira Pak has the potential to capture a "meaningful share" of the U.S. market, where it is competing against Gilead Sciences Inc .

30 Jan 2015

UPDATE 1-Drugmaker AbbVie beats estimates as Humira sales rise

Jan 30 - U.S. drugmaker AbbVie Inc's revenue beat analysts' estimates for the fourth straight quarter as sales of arthritis drug Humira jumped nearly 11 percent.

30 Jan 2015

AbbVie profit beats estimates on higher Humira sales

Jan 30 - U.S. drugmaker AbbVie Inc reported a better-than-expected quarterly adjusted profit due to higher sales of its autoimmune disease drug Humira.

30 Jan 2015

UnitedHealth backs Gilead's Harvoni as preferred hepatitis C treatment

- UnitedHealth Group Inc, the largest U.S. health insurer, on Wednesday backed Gilead Sciences Inc's Harvoni as the preferred hepatitis C treatment on its 2015 commercial drug coverage list, another victory for Gilead over competitor AbbVie Inc.

29 Jan 2015

UPDATE 2-UnitedHealth backs Gilead's Harvoni as preferred hepatitis C treatment

Jan 28 - UnitedHealth Group Inc, the largest U.S. health insurer, on Wednesday backed Gilead Sciences Inc's Harvoni as the preferred hepatitis C treatment on its 2015 commercial drug coverage list, another victory for Gilead over competitor AbbVie Inc.

29 Jan 2015

UnitedHealth backs Gilead's Harvoni as preferred hepatitis C treatment

Jan 28 - UnitedHealth Group Inc on Wednesday backed Gilead Sciences Inc's hepatitis C treatment Harvoni on its 2015 commercial drug coverage list over a new competitor, Viekira Pak from AbbVie Inc.

29 Jan 2015

PBM EnvisionRx chooses Gilead hepatitis C drugs for its formulary

- Pharmacy benefits manager EnvisionRx said on Monday it reached an agreement to provide its customers with Gilead Sciences Inc's hepatitis C drugs on an exclusive basis, the latest Gilead victory in a market share battle with AbbVie over their new treatments for the liver destroying virus.

27 Jan 2015

PBM EnvisionRx chooses Gilead hepatitis C drugs for its formulary

Jan 26 - Pharmacy benefits manager EnvisionRx said on Monday it reached an agreement to provide its customers with Gilead Sciences Inc's hepatitis C drugs on an exclusive basis, the latest Gilead victory in a market share battle with AbbVie over their new treatments for the liver destroying virus.

27 Jan 2015

Express Scripts' Miller says hepatitis C price war to save billions

NEW YORK - Gilead Sciences Inc and AbbVie Inc are in a price war over their hepatitis C treatments that is driving costs lower and has changed the way drugmakers price new medicines, a top executive for pharmacy benefit manager Express Scripts said on Thursday.

22 Jan 2015

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $100.14 -2.24
Pfizer Inc. (PFE.N) $31.25 -0.58
Novartis AG (NOVN.VX) CHF90.15 -0.85
Merck & Co., Inc. (MRK.N) $60.28 -1.81
Roche Holding Ltd. (ROG.VX) CHF248.60 -4.10
Abbott Laboratories (ABT.N) $44.76 -0.50
Eli Lilly and Co (LLY.N) $72.00 -0.11

Earnings vs. Estimates

Search Stocks